BW
IMNM icon

Basepoint Wealth’s Immunome IMNM Stock Holding History

Basepoint Wealth’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93K Hold
91
– – ﹤0.01% 518
2026
Q1 		$1.99K Hold
91
– – ﹤0.01% 535
2025
Q4 		$1.95K Buy
+91
New +$1.6K ﹤0.01% 522

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Basepoint Wealth's IMNM Position: Q2 2026 in Review

Basepoint Wealth held its Immunome (IMNM) position steady in Q2 2026 at 91 shares worth $1.93K. The position accounts for ﹤0.01% of the portfolio, ranked #518.

Basepoint Wealth first reported a position in IMNM in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.99K in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Basepoint Wealth held 91 shares of Immunome worth $1.93K as of Q2 2026.
  • Basepoint Wealth left its Immunome share count unchanged in Q2 2026.
  • Immunome made up ﹤0.01% of Basepoint Wealth's portfolio in Q2 2026, its #518 holding.
  • Basepoint Wealth first reported a position in Immunome in Q4 2025 and has held it in 3 quarters since.
  • Basepoint Wealth's Immunome position peaked at $1.99K in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Basepoint Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.